PITTSBURGH, Oct. 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of Jacek Glinka as president of Mylan's European business, effective Dec. 2, 2013. Glinka will report to Hal Korman, Mylan's chief operating officer.
Prior to joining Mylan, Glinka served as chief executive officer for the Polpharma Group from 2003 to 2006 and from 2009 to 2013. During his tenure, Glinka led the transformation of Polpharma from a small local player into a leading pharmaceutical company in Central and Eastern Europe, the Caucasus and Central Asia. Under his leadership, Polpharma became the leader in the Polish market and one of the fastest growing pharmaceutical companies in the region. From 2011 to 2013, Polpharma doubled its revenue to more than $1 billion. Glinka also led Polpharma in the successful acquisition and integration of a number of businesses including Chimpharm in Kazakhstan; Polfa Warsaw in Poland; the antibiotics division of Bioton in Poland; and the nutraceuticals portfolio of Herbapol. Additionally, Glinka led the company's strategic expansion into new geographies, both organically and through acquisition, including Kazakhstan, Uzbekistan, Azerbaijan and Vietnam. He also enhanced the company's organizational structure and processes, and implemented several corporate-wide cost reduction programs resulting in substantial improvements in Polpharma's profitability.
Mylan CEO Heather Bresch commented, "We are thrilled to welcome Jacek to Mylan. His exceptional track record leading Polpharma speaks for itself and we believe his deep experience in the region will contribute to Mylan's continued success and growth in Europe. We believe Jacek's strong leadership, strategic thinking and operational discipline will build on the solid foundation and leadership team we already have in place, and maximize the many opportunities we see ahead for our European business."
Glinka said, "I have been following Mylan closely for some time and believe its massive global scale, vertical integration, broad product portfolio and unwavering commitment to quality are true differentiators in the highly competitive and diverse European market. I look forward to working with Mylan's global and regional leaders to continue to maximize the power of the Mylan platform across the region and further solidify Mylan's leadership positions in key markets. I also look forward to leveraging my expertise, particularly in the exciting Central and Eastern European markets, to further expand Mylan's footprint."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts